REGENXBIO INC's ticker is RGNX and the CUSIP is 75901B107. A total of 172 filers reported holding REGENXBIO INC in Q1 2023. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185,010 | -13.5% | 11,240 | +19.2% | 0.14% | -29.9% |
| Q4 2022 | $213,895 | -15.5% | 9,431 | -1.6% | 0.19% | -13.8% |
| Q3 2022 | $253,000 | +5.4% | 9,584 | -1.3% | 0.22% | +21.6% |
| Q2 2022 | $240,000 | -32.4% | 9,709 | -9.3% | 0.18% | -13.1% |
| Q1 2022 | $355,000 | -0.3% | 10,709 | -1.7% | 0.21% | +26.8% |
| Q4 2021 | $356,000 | -22.8% | 10,889 | -0.9% | 0.17% | -28.2% |
| Q3 2021 | $461,000 | +8.0% | 10,989 | 0.0% | 0.23% | +13.6% |
| Q2 2021 | $427,000 | +12.7% | 10,989 | -1.1% | 0.21% | +5.6% |
| Q1 2021 | $379,000 | -29.0% | 11,106 | -5.7% | 0.20% | -23.5% |
| Q4 2020 | $534,000 | +56.6% | 11,776 | -5.0% | 0.26% | +43.3% |
| Q3 2020 | $341,000 | -25.2% | 12,401 | +0.1% | 0.18% | -36.7% |
| Q2 2020 | $456,000 | +15.2% | 12,383 | +1.2% | 0.28% | +2.2% |
| Q1 2020 | $396,000 | -19.7% | 12,231 | +1.7% | 0.28% | -13.2% |
| Q4 2019 | $493,000 | +81.9% | 12,031 | +58.2% | 0.32% | +74.2% |
| Q3 2019 | $271,000 | -30.2% | 7,606 | +0.7% | 0.18% | -28.1% |
| Q2 2019 | $388,000 | +660.8% | 7,550 | +1026.9% | 0.25% | +772.4% |
| Q3 2018 | $51,000 | +6.2% | 670 | 0.0% | 0.03% | 0.0% |
| Q2 2018 | $48,000 | – | 670 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RTW INVESTMENTS, LP | 1,459,128 | $110,164,000 | 6.60% |
| ArchPoint Investors | 224,187 | $16,926,000 | 4.60% |
| Redmile Group, LLC | 1,656,065 | $125,033,000 | 3.85% |
| WS MANAGEMENT LLLP | 954,812 | $72,088,000 | 2.37% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 342,000 | $25,821,000 | 1.19% |
| Perceptive Advisors | 470,672 | $35,536,000 | 0.95% |
| Pier Capital, LLC | 94,492 | $7,134,000 | 0.90% |
| Ipswich Investment Management Co., Inc. | 29,932 | $2,260,000 | 0.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 275,000 | $20,763,000 | 0.74% |
| Timpani Capital Management LLC | 27,835 | $2,102,000 | 0.61% |